ADC TOXICITY ATLAS
Payloads & linkers
Linker

VA dipeptide (tesirine)

Cleavable

[H]OC([H])([H])c1c([H])c([H])c(N([H])C(=O)[C@@]([H])(N([H])C(=O)[C@@]([H])(N([H])C(=O)C([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])N([H])C(=O)C([H])([H])C([H])([H])N2C(=O)C([H])=C([H])C2=O)C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])[H])c([H])c1[H]
Physicochemistry

Properties

MW
867.991 Da
TPSA
247.85 Ų
xLogP
-0.2829
Formula
C41H65N5O15
Cleavage
Cleavable
Attachment
Site-specific (engineered Cys)
4 agents

ADCs built on this linker

Agent · target
Ocular
Hepatic
Neutrop.
Thrombo.
Anemia
GI
ILD
Neuro.
MEDI2228TNFRSF17
53.7
24.4
31.7
Camidanlumab tesirineIL2RA
0.9
31.6
16.2
20.5
24.8
27.4
3.4
6.8
Rovalpituzumab tesirineDLL3
0.5
13
9
22
11
24
1.9
Loncastuximab tesirineCD19
0
57
52
58
51
23
0%severity100%
0
Assessed · clear
true 0%
No data
never assessed